Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 5

Sponsor Class

NETWORK 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Plasma cell 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
lestaurtinib × Other hematologic neoplasm × Clear all
NCT00557193 2024-07-15

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 3 Completed
218 enrolled 21 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

NCT00079482 2016-07-21

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
224 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00030186 2012-08-23

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
37 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT00494585 2012-06-25

CEP-701 for PH-negative Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
27 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡